-
Gemtuzumab ozogamicin, sold
under the
brand name Mylotarg®, is an antibody-drug
conjugate (a drug-linked
monoclonal antibody) that is used to
treat acute...
-
Gemtuzumab Ozogamicin:
Reintroduction Based on
Favorable Risk:Benefit Profile". ADCReview.
September 2, 2017.
Retrieved August 14, 2024. "
Gemtuzumab Ozogamicin...
- proteins, its
expression is
known to be tied to TREM2. CD33 is the
target of
gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories),...
- FDA for
cancer include:
Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab Pembrolizumab Ranibizumab...
-
release from the
differentiating promyelocytes. The
monoclonal antibody,
gemtuzumab ozogamicin, has been used
successfully as a
treatment for APL, although...
- bullet" due to
their targeting properties. In 2001 Pfizer/Wyeth's drug
Gemtuzumab ozogamicin (trade name: Mylotarg) was
approved based on a
study with a...
- dimethylhydrazide. It
includes the same linker,
called "AcBut", and toxin, as
gemtuzumab ozogamicin,
which arose from the same collaboration. The
linker is a carbonyl-containing...
-
traditional systemic approaches. The
first approved drug of this type was
gemtuzumab ozogamicin (Mylotarg),
released by
Wyeth (now Pfizer). The drug was approved...
-
Union Liver toxicity.
Gatifloxacin 2006 US
Increased risk of dysglycemia.
Gemtuzumab ozogamicin (Mylotarg) 2010 US No
improvement in
clinical benefit; risk...
- antiquity. Antibody-drug
conjugates using calicheamicins as
cytotoxic agents:
Gemtuzumab ozogamicin Inotuzumab ozogamicin Maiese,
William M; Lechevalier, Mary...
